Experimental lymphoma drug ASTX660 tested in tiny, terminated trial
NCT ID NCT04362007
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested the drug ASTX660 in just 8 people with T-cell lymphoma that had returned or not responded to prior treatments. The study aimed to find a safe dose and check for side effects, but it was stopped early. Because it was so small and incomplete, we cannot draw firm conclusions about whether ASTX660 works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ASTX660
- What this could lead to
- If it works, this could point toward a new treatment option for people with T-cell lymphoma that has not responded to other therapies.
- What could go wrong
- This was a very early, small trial that was terminated early, so we don't have enough data to know if ASTX660 is safe or effective. Many early-stage cancer drugs fail in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY ADULT T-CELL LEUKEMIA LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Yamagata University Hospital
Yamagata, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug duo outsmart resistant T-Cell lymphoma?
- Experimental drug chidamide targets Hard-to-Treat blood cancer
- New drug duo targets hard-to-treat blood cancers
- New pill shows promise for Hard-to-Treat cancers
- New hope for tough lymphoma: drug combo trial launches
- Experimental drug brincidofovir targets Hard-to-Treat lymphomas